ArticleFrontiers in pharmacology2026
Pretreatment myopia progression is associated with the response to 0.01% atropine: a
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To determine which subgroup of children would best benefit from 0.01% atropine eyedrop. Methods: This Results: After 1 year of 0.01% atropine treatment, SEP was -0.37 ± 0.23 D, -0.57 ± 0.38 D, and -0.68 ± 0.49 D in the slow, moderate, and fast progression groups (P = 0.17). The group with faster SEP during the first year still showed faster SEP after treatment. The reduction of SEP (SEP of the second year minus SEP of the first year) in the moderate group was more than that in the slow group (0.22 ± 0.37 D vs. -0.10 ± 0.21 D, P = 0.007); the fast group was more than that in the slow group (0.57 ± 0.55 D vs. -0.10 ± 0.21 D, P < 0.001) and the moderate group (0.57 ± 0.55 D vs. 0.22 ± 0.37 D, P = 0.02). Faster SEP before treatment is related to the reduction efficiency (β = -0.5, P = 0.01). Conclusion: Faster SEP before treatment is associated with a better treatment response to 0.01% atropine eye drops, with greater reduction in SEP after treatment. However, no significant association was found between baseline progression and axial elongation changes. Children with slow SEP cannot get significant myopia control benefit from 1-year 0.01% atropine treatment. Clinical Trial Registration: clinicaltrials.gov, identifier ChiCTR-IOR-17013898.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.